Treatment success rate: XDR-TB cases in South-East Asia (WHO region)
South-East Asia (WHO region): Treatment success rate: XDR-TB cases was 73 in 2022. ▲ Rising
Latest (2022)
73
Change on year
up 4.3%
Rank
2nd
of 11 groups
All-time high
73
in 2022
All-time low
28
in 2015
Years of data
12
2011–2022
Treatment success rate: XDR-TB cases in South-East Asia (WHO region), 2011–2022
Source: World Health Organization, Global Health Observatory.
Analysis
The most recent figure for treatment success rate: xdr-tb cases in South-East Asia (WHO region) is 73, measured in 2022. That is the highest value across all 12 years on record.
Compared with earlier readings it is up 4.3% on the previous year and up 121.2% over ten years.
Over the whole period, treatment success rate: xdr-tb cases in South-East Asia (WHO region) peaked at 73 in 2022 and was at its lowest, 28, in 2015.
The long-run direction has been consistently rising across the 12 years of available data.
Treatment success rate: XDR-TB cases in South-East Asia (WHO region), year by year
| Year | Value | Change |
|---|---|---|
| 2011 | 35 | — |
| 2012 | 33 | -5.7% |
| 2013 | 33 | +0.0% |
| 2014 | 29 | -12.1% |
| 2015 | 28 | -3.4% |
| 2016 | 31 | +10.7% |
| 2017 | 37 | +19.4% |
| 2018 | 48 | +29.7% |
| 2019 | 57 | +18.8% |
| 2020 | 64 | +12.3% |
| 2021 | 70 | +9.4% |
| 2022 | 73 | +4.3% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 36.78 | 28 | 57 | 9 |
| 2020s | 69 | 64 | 73 | 3 |
Countries ranked near South-East Asia (WHO region)
- 1 Australia 100 compare
- 1 Nicaragua 100 compare
- 1 United States of America 100 compare
- 1 Equatorial Guinea 100 compare
- 1 Tanzania, United Republic of 100 compare
- 1 Morocco 100 compare
- 1 Hong Kong, China 100 compare
- 1 Papua New Guinea 100 compare
- 1 Niger 100 compare
- 1 Portugal 100 compare
- 1 Israel 100 compare
- 1 Botswana 100 compare
- 1 Congo, Democratic Republic of the 100 compare
- 1 Cameroon 100 compare
- 1 Panama 100 compare
- 1 Somalia 100 compare
- 1 Canada 100
More health data for South-East Asia (WHO region)
- Pertussis - number of reported cases, gaps filled 2,449 (2025)
- Total tetanus - number of reported cases, gaps filled 164 (2025)
- Neonatal tetanus - number of reported cases, gaps filled 84 (2025)
- Measles - number of reported cases, gaps filled 19,075 (2025)
- Diphtheria - number of reported cases, gaps filled 3,416 (2025)
- Number of under-five deaths, annual growth rate -4.64 % change on previous year (2024)
- Number of neonatal deaths, annual growth rate -4.57 % change on previous year (2024)
- Number of infant deaths, annual growth rate -4.21 % change on previous year (2024)
- Measles - number of reported cases, annual growth rate -30.44 % change on previous year (2025)
- Pertussis - number of reported cases, annual growth rate -67.98 % change on previous year (2025)
Frequently asked questions
- What is treatment success rate: xdr-tb cases in South-East Asia (WHO region)?
- Treatment success rate: xdr-tb cases in South-East Asia (WHO region) was 73 in 2022, according to World Health Organization, Global Health Observatory.
- What is the highest treatment success rate: xdr-tb cases recorded in South-East Asia (WHO region)?
- The highest recorded value was 73 in 2022.
- What is the lowest treatment success rate: xdr-tb cases recorded in South-East Asia (WHO region)?
- The lowest recorded value was 28 in 2015.
- How does South-East Asia (WHO region) rank for treatment success rate: xdr-tb cases?
- South-East Asia (WHO region) ranks 2nd out of 11 groups with data for 2022.
- Is treatment success rate: xdr-tb cases rising or falling in South-East Asia (WHO region)?
- Over the last ten years it is up 121.2%. The long-run trend across the full record is rising.
- Where does this South-East Asia (WHO region) data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Treatment success rate: XDR-TB cases. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 12 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).